{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:14:12Z","timestamp":1789740852640,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T00:00:00Z","timestamp":1462320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.yrtph.2016.05.002","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T10:07:12Z","timestamp":1462442832000},"page":"348-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials"],"prefix":"10.1016","volume":"80","author":[{"given":"Andy N.","family":"Mead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid R.","family":"Amouzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Ewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Giarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Jordaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Traebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2016.05.002_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/026119291404200306","article-title":"An analysis of the use of animal models in predicting human toxicology and drug safety","volume":"42","author":"Bailey","year":"2014","journal-title":"Altern. Lab. Anim."},{"key":"10.1016\/j.yrtph.2016.05.002_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/faat.1997.2357","article-title":"Evaluation of effect profiles: functional observational battery outcomes","volume":"40","author":"Baird","year":"1997","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vascn.2014.07.005","article-title":"Telemetry video-electroencephalography (EEG) in rats, dogs and non-human primates: methods in follow-up safety pharmacology seizure liability assessments","volume":"70","author":"Bassett","year":"2014","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0892-0362(96)00064-5","article-title":"Functional observational battery comparing effects of ethanol, 1,1,1-trichloroethane, ether, and flurothyl","volume":"18","author":"Bowen","year":"1996","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2016.05.002_bib5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/adc.2006.111633","article-title":"Quantifying how tests reduce diagnostic uncertainty","volume":"92","author":"Coulthard","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.yrtph.2016.05.002_bib6","series-title":"Society of Toxicology Annual Meeting. San Diego","article-title":"Developing a heat map for CNS profiling based on the Irwin test","author":"de Ron","year":"2015"},{"key":"10.1016\/j.yrtph.2016.05.002_bib7","series-title":"Guideline on Regulatory Acceptance of 3R (Replacement, Reduction, Refinement) Testing Approaches","author":"EMA","year":"2014"},{"key":"10.1016\/j.yrtph.2016.05.002_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","article-title":"The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative","volume":"142","author":"Ewart","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2016.05.002_bib32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.vascn.2013.04.008","article-title":"A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions","volume":"68","author":"Ewart","year":"2013","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/009286150103500134","article-title":"Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceuticals markets \u2014 1960 to 1999","volume":"35","author":"Fung","year":"2001","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.yrtph.2016.05.002_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/0269881112466185","article-title":"The failure of the antidepressant drug discovery process is systemic","volume":"27","author":"Hendrie","year":"2013","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1476-5381.2009.00176.x","article-title":"Opportunities for the replacement of animals in the study of nausea and vomiting","volume":"157","author":"Holmes","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib12","series-title":"ICHS7A: Safety Pharmacology Studies for Human Pharmaceuticals","author":"ICHS7A","year":"2001"},{"key":"10.1016\/j.yrtph.2016.05.002_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2131\/jts.20.77","article-title":"Predictability of clinical adverse reactions of drugs by general pharmacology studies","volume":"20","author":"Igarashi","year":"1995","journal-title":"J.\u00a0Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2016.05.002_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF00401402","article-title":"Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse","volume":"13","author":"Irwin","year":"1968","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.yrtph.2016.05.002_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2005.08.050","article-title":"Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats","volume":"522","author":"Ivarsson","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vascn.2015.08.012","article-title":"Rodent big brother: development and validation of a home cage automated behavioural monitoring system for use in safety pharmacology studies in rats","volume":"75","author":"Leslie","year":"2015","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.physbeh.2005.04.009","article-title":"Pica\u2013a model of nausea? species differences in response to cisplatin","volume":"85","author":"Liu","year":"2005","journal-title":"Physiol. Behav."},{"issue":"1","key":"10.1016\/j.yrtph.2016.05.002_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.vascn.2011.03.003","article-title":"Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies","volume":"64","author":"Lynch","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1258\/jrsm.2007.070164","article-title":"Medical progress depends on animal models \u2013 doesn't it?","volume":"101","author":"Matthews","year":"2008","journal-title":"J.\u00a0R. Soc. Med."},{"key":"10.1016\/j.yrtph.2016.05.002_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3109\/10915819609008716","article-title":"A performance standard for clinical and functional observational battery examination of rats","volume":"15","author":"Mattson","year":"1996","journal-title":"J. Am. Coll. Toxicol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.vascn.2007.03.007","article-title":"An optimised methodology for the neurobehavioural assessment in rodents","volume":"56","author":"Moscardo","year":"2007","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/toxsci\/kfr334","article-title":"Application of data mining and visualization techniques for the prediction of drug-induced nausea in man","volume":"126","author":"Parkinson","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2016.05.002_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.vascn.2014.08.004","article-title":"Safety pharmacology in 2014: new focus on non-cardiac methods and models","volume":"70","author":"Pugsley","year":"2014","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"issue":"1","key":"10.1016\/j.yrtph.2016.05.002_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.vascn.2005.05.003","article-title":"Validation of a motor activity system by a robotically controlled vehicle and using standard reference compounds","volume":"52","author":"Patterson","year":"2005","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vascn.2005.04.005","article-title":"Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds","volume":"52","author":"Redfern","year":"2005","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1472-8206.2002.00098.x","article-title":"Safety pharmacology\u2013a progressive approach","volume":"16","author":"Redfern","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/00365513.2010.501382","article-title":"Visualizing the impact of prevalence on a diagnostic test","volume":"70","author":"Rehling","year":"2010","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.yrtph.2016.05.002_bib26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2131\/jts.38.581","article-title":"Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan","volume":"38","author":"Tamaki","year":"2013","journal-title":"J.\u00a0Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2016.05.002_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.vascn.2009.05.011","article-title":"A\u00a0framework to assess the translation of safety pharmacology data to humans","volume":"60","author":"Valentin","year":"2009","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vascn.2008.05.007","article-title":"Safety and secondary pharmacology: successes, threats, challenges and opportunities","volume":"58","author":"Valentin","year":"2008","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2016.05.002_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.yrtph.2012.09.002","article-title":"The ability of animal studies to detect serious post marketing adverse events is limited","volume":"64","author":"van Meer","year":"2012","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2016.05.002_bib30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1152\/jn.00121.2010","article-title":"Investigating neural correlates of behavior in freely behaving rodents using inertial sensors","volume":"104","author":"Venkatraman","year":"2010","journal-title":"J.\u00a0Neurophysiol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230016301052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230016301052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:29:08Z","timestamp":1759494548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230016301052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":35,"alternative-id":["S0273230016301052"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2016.05.002","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2016.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}